Skip to main content

Pharmacology Articles

 

Clinical courses

  • A REVIEW- LIVING WITH BUTTERFLY SKIN DISEASE

    About Authors:
    Mohd. Yaqub Khan*, Poonam Gupta, Bipin Bihari, Vinod Kumar Singh, Sanjay Kumar Yadav, Aparna Misra
    Saroj Institute of Technology & Management,
    Ahimamau P.O. Arjunganj Sultanpur Road, Lucknow  -226002
    *khanishaan16@yahoo.com

  • A REVIEW ON HISTAMINE ANTAGONIST

    About Authors:
    Mahaveer Kabra*1, Sanjay Bhandari1,  Ami Sharma1, Reema Jain2
    Department of Pharmacology,
    1Kota College of Pharmacy, Kota
    2Bhupal Noble’s Institute of Pharmaceutical science, Udaipur
    *sanskarkabra@gmail.com

  • NOVEL SYNTHETIC APPROACHES FOR THE TREATMENT OF MALIGNANT MELANOMA UNDER CLINICAL TRIAL

    ABOUT AUTHORS:
    Tara Shankar Basuri1*, Ishvar Parmar1, Vishal Modi2, Virag Shah3, Niyatee Thakur4
    SSR College of pharmacy, Silvassa,
    U.T of Dadra & Nagar Haveli-396230
    *tbasuri@gmail.com

    ABSTRACT
    Malignant melanoma is the most lethal form of skin cancer and an increasingly common disease worldwide. It remains one of the most treatment-refractory malignancies. The current treatment options for patients with metastatic melanoma are limited and in most cases non-curative. This review focuses on novel synthetic and herbal drugs for malignant melanoma treatment, by a single or combinational agent approach. These molecules are widely used by the oncologists for the treatment of this type of cancer. So this review can help to the public to aware the malignant melanoma and its treatment and novel target for its treatment.

  • THERMAL THERAPY: A POTENTIAL COMBINED APPROACH IN CANCER TREATMENT

    About Author:
    Banwari Lal Gupta
    L.R.S. Institute of Tuberculosis & Respiratory Diseases,
    New Delhi-110030
    banwarigupta141@gmail.com

    Abstract
    Despite decades of research and drug development for cancer treatment, cancer still remains one of the major causes of human death in the world. An important aspect in cancer therapy is the development of a targeted drug delivery system that decreases the toxic side effects of chemotherapy and other cancer therapies. The current conventional method in treating cancer involves inserting catheters to allow for chemotherapy, to reduce the amount of cancer present, and/or then to surgically remove the tumors, followed by more chemotherapy and radiation sessions.
    Research on thermal therapy- the heating of pathological tissue using energy source (radiofrequency, microwave, high-intensity focused ultrasound or laser energy and cryosurgery. There are clear reasons for using hyperthermia in cancer treatment. Treatment at temperatures between 40-44°C is cytotoxic for cells in low pO2 and low pH environmental conditions, which are found specifically within the tumor tissue, due to insufficient blood perfusion. Under such conditions radiotherapy is less effective, and systematically applied cytotoxic agents will reach such area in lower concentrations then in well perfused area. Therefore the addition of hyperthermia to chemotherapy or radiotherapy will result in at least an additive effect. Furthermore, the effects of both radiotherapy and many drugs are enhanced at an increased temperature. Hyperthermia can be allied by several methods such as: local hyperthermia, regional hyperthermia, and whole-body hyperthermia.
    Countless researches are on their way, in the relation of improvement of heating techniques, development of hyperthermia planning models and thermometry. The clinical studies have confirmed future expectations of hyperthermiawould be valuable. Hyperthermia is a potential combined approach and deserving more attention for its further development. This article will throw the lights on hyperthermia therapy for improvement of cancer treatment.

  • ROLE OF ASPIRIN IN CANCER PREVENTION

    About Author:
    Patelia Emanual Michael
    Department of pharmacology, University of Bedfordshire,
    United Kingdom, LU1 3JU.
    ricky.emanual@gmail.com

  • DETERMINATION OF EFFECT OF DIETHYL MALEATE ON iNOS EXPRESSION AND CELL VIABILITY

    About Authors:
    *Ravi Patel, Dr Shori Thakur
    Pharmacy and Pharmaceutical Science Department,
    University of Hertfordshire, Hatfield
    AL10 9AB, United Kingdom
    Ravi_pharmacology@yahoo.com, Ravipatel12345@gmail.com

  • PHARMACOVIGILANCE SYSTEM IN WORLD

    ABOUT AUTHOR:
    Vishwa Deepak kumar
    Departement of Pharmacy,
    IEC group of institution,
    Greater Noida (U.P), Pin- 201301
    vdkumar.iec@gmail.com

  • A REVIEW ON METFORMIN AND ITS LIFE THREATENING ADVERSE EFFECT

    ABOUT AUTHOR:
    Amitava Sinha Ray
    Department of Pharmacy,
    Bengal School of Technology
    West Bengal University of Technology, West Bengal
    a.amitava.s@gmail.com

  • HERBAL TREATMENT AND RHEUMATOID ARTHRITIS: AN OVERVIEW

    About Authors:
    Prabhakar Sharma*1, Prakash Pandey1, Sunil Roshan1, Ashish Garg2, Vikas Pandey3, Anil Pasi4
    1Department of Pharmacognosy, GRKIST (Pharmacy), Jabalpur, M.P.
    2Department of Pharmaceutics, GRKIST (Pharmacy), Jabalpur, M.P.
    3Department of chemistry, RDVV, Jabalpur, M.P.

  • A REVIEW ON CLINICAL APPLICATION OF CLOPIDOGREL IN ACUTE CORONARY SYNDROME

    ABOUT AUTHORS:
    Tripti Verma*, Keshav Vashistha, Sachin Vispute
    B N College of Pharmacy,
    Udaipur, Rajasthan
    *triptiphsoni22@gmail.com

    ABSTRACT:
    The review examines the recent  trials of clopidogrel in the treatment of acute coronary syndromes, as well as current cardiac guidelines from several professional societies. As the publication of the landmark study Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), the clinical benefit of early and intermediate-term use of combined antiplatelet agents--clopidogrel plus aspirin--in non-ST-segment elevation myocardial infarction (NSTEMI) patients became evident. Pretreatment and intermediate-term therapy with clopidogrel in NSTEMI ACS patients undergoing percutaneous coronary intervention (PCI) was further supported by the PCI-CURE trial. Recently, the results of two major trials Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28, Clopidogrel and Metoprolol in Myocardial Infarction Trial established the pivotal role of clopidogrel in the other spectrum of ACS-STEMI. Coupled with the results from previous multicentre trials, these two studies provide a guide for the early and long-term use of clopidogrel in the whole spectrum of ACS. A review summarising the results of the recent clinical trials and a discussion on its implications for the clinical management of ACS is presented.Clopidogrel is well established in the treatment of acute coronary syndromes and is ubiquitous in cardiology practice. Landmark studies have established the importance of clopidogrel in the treatment of non-ST and ST elevation myocardial infarction and in percutaneous coronary intervention by reducing death, reinfarction, and adverse cardiac events.

Subscribe to Pharmacology Articles